Mary Gail Mercurio

Mary Gail Mercurio

Auto-generated profile, based on publicly available information

Mary Gail Mercurio

Department of Dermatology, University of Rochester Medical Center, Rochester, New York

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in JAAD Case Reports
Verified
Journal Article
Open access
JPJay Patel
Jay Patel
MGMariana Chrispim Gimenez
Mariana Chrispim Gimenez
MMMary Gail Mercurio
Mary Gail Mercurio

28 October 2025 in JAAD Case Reports
Verified
Journal Article
Open access
JPJay R. Patel
Jay R. Patel
VVVedha Vaddaraju
Vedha Vaddaraju
JDJennifer Dykeman
Jennifer Dykeman
ETEran Tallis
Eran Tallis
KMKathleen Mannava
Kathleen Mannava
MMMary Gail Mercurio
Mary Gail Mercurio

16 March 2026 in International Journal of Medical Students
Verified
Journal Article
Open access
PDF file
AOAmanda Rodriguez Orengo
Amanda Rodriguez Orengo
AMAlicia Mizes
Alicia Mizes
ILIrina Lerman
Irina Lerman
AFAbigail I. Franco
Abigail I. Franco
MMMary Gail Mercurio
Mary Gail Mercurio
PBPaul Blackcloud
Paul Blackcloud
Background: Immune checkpoint inhibitors (ICIs), including therapies targeting anti-programmed cell death protein 1 (PD-1) or anti-programmed death-ligand 1 (PDL-1), are highly effective for treating various malignancies, but are often associated with immune-related adverse events (irAEs). Among these, cutaneous irAEs are the most prevalent, affecting about half of patients and varying widely in severity. irAEs can impact quality of life and lead to treatment discontinuation. Managing these side effects effectively is essential to allow continuation of therapy without compromising its efficacy. Methods: Retrospective case series. Results: We present three patients who developed severe cutaneous irAEs: two with pembrolizumab-induced lichenoid dermatitis and one with atezolizumab-induced psoriasiform rash. Initial treatment was guided by histopathologic findings, leading to the use of dupilumab, an interleukin-4 receptor (IL-4Ra) monoclonal antibody, in all three cases. While two patients achieved full resolution with dupilumab, the third case, which progressed to a clinically psoriasiform morphology, was later treated with apremilast, a phosphodiesterase 4 (PDE4) inhibitor, resulting in significant improvement. Conclusion: These cases highlight the critical role of combining histopathologic and clinical insights to customize treatment approaches. Both dupilumab and apremilast are steroid-sparing options with favorable safety profiles and offer effective alternatives to systemic corticosteroids without compromising the efficacy of ICIs.